p-ErbB2/HER2 Antibody (19G5): sc-81528

p-Neu Antibody (19G5) is a mouse monoclonal IgG1 antibody that detects Neu in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), and immunofluorescence (IF). anti-p-Neu antibody (19G5) specifically recognizes phosphorylated forms of Neu, which is crucial for understanding cellular signaling pathways. Neu, also known as HER2, is a member of the ErbB family of receptor tyrosine kinases and plays a significant role in cell proliferation and differentiation. Neu is primarily located at the cell membrane, where interactions with various ligands and other proteins facilitate critical signaling cascades that regulate cell growth and survival. Aberrant activation of Neu through phosphorylation can lead to oncogenic signaling, contributing to the development of aggressive cancers, including breast, gastric, and esophageal tumors. Phosphorylation of Neu at specific tyrosine residues, such as Tyr 1248, promotes recruitment of signaling proteins like GRB2 and Shc, which are essential for transducing extracellular signals into cellular responses. Using p-Neu monoclonal antibody (19G5) in research can provide valuable insights into mechanisms of Neu-mediated signaling and implications in cancer biology.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

p-ErbB2/HER2 Antibody (19G5) References:

1. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation.  |  Zhou, BP., et al. 2001. Nat Cell Biol. 3: 973-82. PMID: 11715018
2. Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment.  |  Hudelist, G., et al. 2003. Br J Cancer. 89: 983-91. PMID: 12966413
3. Androgen-dependent regulation of Her-2/neu in prostate cancer cells.  |  Berger, R., et al. 2006. Cancer Res. 66: 5723-8. PMID: 16740710
4. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.  |  Osipo, C., et al. 2007. Int J Oncol. 30: 509-20. PMID: 17203234
5. Ganglioside GM(3) is stably associated to tyrosine-phosphorylated ErbB2/EGFR receptor complexes and EGFR monomers, but not to ErbB2.  |  Milani, S., et al. 2007. Biochim Biophys Acta. 1771: 873-8. PMID: 17521961
6. The nuclear receptor coactivator amplified in breast cancer-1 is required for Neu (ErbB2/HER2) activation, signaling, and mammary tumorigenesis in mice.  |  Fereshteh, MP., et al. 2008. Cancer Res. 68: 3697-706. PMID: 18483252
7. Transmembrane domain targeting peptide antagonizing ErbB2/Neu inhibits breast tumor growth and metastasis.  |  Arpel, A., et al. 2014. Cell Rep. 8: 1714-1721. PMID: 25220456
8. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.  |  Bonazzoli, E., et al. 2019. Gynecol Oncol. 153: 158-164. PMID: 30630630
9. Evaluation of the Expression EGFR, HER2/NEU and the End Effector ERK of the RAS/RAF/MAP Kinase Pathway in Prostatic Adenocarcinoma for a Possible Role as New Target Therapy.  |  Shalaby, A., et al. 2024. Asian Pac J Cancer Prev. 25: 2193-2201. PMID: 38918683
10. Involvement of tyrosine phosphorylation of p185(c-erbB2/neu) in tumorigenicity induced by X-rays and the neu oncogene in human breast epithelial cells.  |  Kang, KS., et al. 1998. Mol Carcinog. 21: 225-33. PMID: 9585252

The preferred antibody is Antibody (): sc-8.